Harm Wienbergen

Prof. Harm Wienbergen


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2020 in European Heart Journal
Verified
Journal Article
Closed access
HTHolger Thiele
Holger Thiele
TKThomas Kurz
Thomas Kurz
HFHans-Josef Feistritzer
Hans-Josef Feistritzer
GSGeorg Stachel
Georg Stachel
PHPhilipp Hartung
Philipp Hartung
SDSteffen Desch
Steffen Desch
Aims: Transcatheter aortic valve implantation (TAVI) has emerged as established treatment option in patients with symptomatic aortic stenosis. Technical developments in valve design have addressed previous limitations such as suboptimal deployment, conduction disturbances, and paravalvular leakage. However, there are only limited data available for the comparison of newer generation self-expandable valve (SEV) and balloon-expandable valve (BEV). Methods and results: SOLVE-TAVI is a multicentre, open-label, 2 × 2 factorial, randomized trial of 447 patients with aortic stenosis undergoing transfemoral TAVI comparing SEV (Evolut R, Medtronic Inc., Minneapolis, MN, USA) with BEV (Sapien 3, Edwards Lifesciences, Irvine, CA, USA). The primary efficacy composite endpoint of all-cause mortality, stroke, moderate/severe prosthetic valve regurgitation, and permanent pacemaker implantation at 30 days was powered for equivalence (equivalence margin 10% with significance level 0.05). The primary composite endpoint occurred in 28.4% of SEV patients and 26.1% of BEV patients meeting the prespecified criteria of equivalence [rate difference −2.39 (90% confidence interval, CI −9.45 to 4.66); P equivalence = 0.04]. Event rates for the individual components were as follows: all-cause mortality 3.2% vs. 2.3% [rate difference −0.93 (90% CI −4.78 to 2.92); P equivalence < 0.001], stroke 0.5% vs. 4.7% [rate difference 4.20 (90% CI 0.12 to 8.27); P equivalence = 0.003], moderate/severe paravalvular leak 3.4% vs. 1.5% [rate difference −1.89 (90% CI −5.86 to 2.08); P equivalence = 0.0001], and permanent pacemaker implantation 23.0% vs. 19.2% [rate difference −3.85 (90% CI −10.41 to 2.72) in SEV vs. BEV patients; P equivalence = 0.06]. Conclusion: In patients with aortic stenosis undergoing transfemoral TAVI, newer generation SEV and BEV are equivalent for the primary valve-related efficacy endpoint. These findings support the safe application of these newer generation percutaneous valves in the majority of patients with some specific preferences based on individual valve anatomy.

1 December 2015 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AFAndreas Fach
Andreas Fach
SBStefanie Bünger
Stefanie Bünger
RZRobert Zabrocki
Robert Zabrocki
JSJohannes Schmucker
Johannes Schmucker
PCPaulina Conradi
Paulina Conradi
HWHarm Wienbergen
Harm Wienbergen

18 June 2018 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
HWHarm Wienbergen
Harm Wienbergen
AFAndreas Fach
Andreas Fach
SMSven Meyer
Sven Meyer
JMJochen Meyer
Jochen Meyer
JSJanina Stehmeier
Janina Stehmeier
RHRainer Hambrecht
Rainer Hambrecht
Long-term risk factor control after myocardial infarction (MI) is currently inadequate and there is an unmet need for effective secondary prevention programmes. It was the aim of the study to compare a 12-month intensive prevention programme (IPP), coordinated by prevention assistants and including education sessions, telephone visits and telemetric risk factor control, with usual care after MI. Three hundred and ten patients were randomized to IPP vs. usual care one month after hospital discharge for MI in two German heart centres. Primary study endpoint was the IPP Prevention Score (0–15 points) quantifying global risk factor control. Global risk factor control was strongly improved directly after MI before the beginning of the randomized study (30% increase IPP Prevention Score). During the 12-month course of the randomized trial the IPP Prevention Score was improved by a further 14.3% in the IPP group (p < 0.001), while it decreased by 11.8% in the usual care group (p < 0.001). IPP significantly reduced smoking, low-density lipoprotein cholesterol, systolic blood pressure and physical inactivity compared with usual care (p < 0.05). Step counters with online documentation were used by the majority of patients (80%). Quality of life was significantly improved by IPP (p < 0.05). The composite endpoint of adverse clinical events was slightly lower in the IPP group during 12 months (13.8% vs. 18.9%, p = 0.25). A novel intensive prevention programme after MI, coordinated by prevention assistants and using personal teachings and telemetric strategies for 12 months, was significantly superior to usual care in providing sustainable risk factor control and better quality of life.

1 July 2022 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
PDF file
HWHarm Wienbergen
Harm Wienbergen
DBDaniel Boakye
Daniel Boakye
KGKathrin Günther
Kathrin Günther
JSJohannes Schmucker
Johannes Schmucker
LMLuis Alberto Mata Marín
Luis Alberto Mata Marín
WAWolfgang Ahrens
Wolfgang Ahrens
Aims: Family history is a known risk factor for early-onset myocardial infarction (EOMI). However, the role of modifiable lifestyle and metabolic factors in EOMI risk is unclear and may differ from that of older adults. Methods: This case-control study included myocardial infarction (MI) patients aged ≤45 years from the Bremen ST-elevation MI Registry and matched controls randomly selected from the general population (German National Cohort) at the same geographical region. Multiple logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the individual and combined associations of lifestyle and metabolic factors with EOMI risk, overall and according to family history for premature MI. Results: A total of 522 cases and 1191 controls were included. Hypertension, current smoking, elevated waist-to-hip ratio, and diabetes mellitus were strongly associated with the occurrence of EOMI. By contrast, higher frequency of alcohol consumption was associated with decreased EOMI risk. In a combined analysis of the risk factors hypertension, current smoking, body mass index ≥25.0 kg/sqm, and diabetes mellitus, participants having one (OR = 5.4, 95%CI = 2.9–10.1) and two or more risk factors (OR = 42.3, 95%CI = 22.3–80.4) had substantially higher odds of EOMI compared to those with none of these risk factors, regardless of their family history. Conclusion: This study demonstrates a strong association of smoking and metabolic risk factors with the occurrence of EOMI. The data suggest that the risk of EOMI goes beyond family history and underlines the importance of primary prevention efforts to reduce smoking and metabolic syndrome in young persons.

1 December 2016 in The American Journal of Cardiology
Verified
Journal Article
Closed access
HWHarm Wienbergen
Harm Wienbergen
OPOtmar Pfister
Otmar Pfister
MHMatthias Hochadel
Matthias Hochadel
SMStephan Michel
Stephan Michel
OBOliver Bruder
Oliver Bruder
RGRAID-HF (Registry Analysis of Iron Deficiency–Heart Failure) REGISTRY Study Group
RAID-HF (Registry Analysis of Iron Deficiency–Heart Failure) REGISTRY Study Group

1 September 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
IEIngo Eitel
Ingo Eitel
RSRoza Saraei
Roza Saraei
DJDominik Jurczyk
Dominik Jurczyk
AFAndreas Fach
Andreas Fach
RHRainer Hambrecht
Rainer Hambrecht
TSThomas Stiermaier
Thomas Stiermaier
Background and Aims: Glycoprotein (GP) IIb/IIIa inhibitors are recommended in acute myocardial infarction (AMI) for bailout treatment in case of angiographic microvascular obstruction (MVO), also termed no-reflow phenomenon, after percutaneous coronary intervention (PCI) with, however, lacking evidence (class IIa, level C). Methods: The investigator-initiated, international, multicentre REVERSE-FLOW trial randomized 120 patients with AMI and thrombolysis in myocardial infarction flow grade ≤ 2 after primary PCI to optimal medical therapy with or without GP IIb/IIIa inhibitor. The primary endpoint was infarct size [percentage of left ventricular (LV) mass assessed by cardiac magnetic resonance (CMR). Secondary endpoints included CMR-derived MVO and 30-day adverse clinical events. The trial is registered with ClinicalTrials.gov: NCT02739711. Results: The population was predominantly male (76.7%) with a median age of 66 years and ST-elevation myocardial infarction in 73.3% of patients. Clinical and angiographic characteristics were well balanced between the cohorts. Patients in the treatment group (n = 62) received eptifibatide (n = 41) or tirofiban (n = 21). Infarct size assessed by CMR imaging was similar in both study groups [25.4% of LV mass (%LV) vs. 25.2%LV; P = .386]. However, the number of patients with evidence of CMR-derived MVO (74.5% vs. 92.2%; P = .017) and the extent of MVO (2.1%LV vs. 3.4%LV; P = .025) were significantly reduced in the GP IIb/IIIa inhibitor group compared with controls. Thirty-day outcome showed an increased bleeding risk after GP IIb/IIIa inhibitor administration restricted to non–life-threatening bleedings (22.6% vs. 6.9%; P = .016) without differences in all-cause mortality (4.8% vs. 3.4%; P = .703). Conclusions: Bailout GP IIb/IIIa inhibition in AMI patients with angiographic MVO failed to reduce the primary endpoint infarct size but decreased CMR-derived MVO and led to an increase in non-fatal bleeding events.